Furthermore, considering IMpassion130 study results, the FDA approved therapy with atezolizumab (a PD-L1 antibody) and chemotherapy (nab-paclitaxel) for PD-L1-positive and metastatic triple-negative breast cancer (TNBC) in March 2019 [12]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.